ZLAB: Zai Lab Ltd insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
92 institutions reported holding $813.14M of Zai Lab Ltd on Form 13F (99 the quarter before). 14 opened a new position and 21 sold out. Shares held by institutions: +56%.
| Largest holders | Shares | Value |
|---|---|---|
| RTW INVESTMENTS, LP | 6,574,032 | $124.91M |
| TCG Crossover Management, LLC | 6,137,627 | $116.61M |
| RA CAPITAL MANAGEMENT, L.P. | 5,743,533 | $109.13M |
| ADAR1 Capital Management, LLC | 3,369,034 | $64.01M |
| FMR LLC | 2,815,214 | $53.49M |
| GOLDMAN SACHS GROUP INC | 2,315,480 | $43.99M |
| Woodline Partners LP | 2,207,293 | $41.94M |
| Frazier Life Sciences Management, L.P. | 1,902,320 | $36.14M |
| BAMCO INC /NY/ | 1,623,694 | $30.85M |
| TWO SIGMA INVESTMENTS, LP | 1,299,394 | $24.69M |
Clinical trial readouts
2 Phase 2 or 3 trials by Zai Lab Ltd with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-03-14 (est.) | ZL-1109 (VRDN-003) | Thyroid Eye Disease (TED) | Phase 3 | 108 | Enrollment complete | NCT07211776 |
| 2027-08 (est.) | ZL-1310 | Solid Tumors | Phase 1/2 | 166 | Recruiting | NCT06885281 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.